Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Switzerland

Our Life Sciences & Healthcare team consists of specialised attorneys who will advise and represent you in all legal matters competently and tailored to the special needs of your company. 

With more than 300 lawyers specialising in the Life Sciences & Healthcare sector worldwide and the support of the Life Sciences Asia Pacific Network (LAN), we at CMS are very familiar with the economic, commercial and legal needs of our clients in those industries.

Reputation

We have been working successfully for many years with leading companies in the Life Sciences sector in the fields of pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs and cosmetics. These include the world’s most important pharmaceutical companies and the world’s leading medical device companies. In the Healthcare sector, we advise and represent all relevant medical service providers (hospitals, HMOs, nursing homes, laboratories, physicians, pharmacists, etc.) and their associations.

Comprehensive advice and representation

We regularly advise our Life Sciences clients on their day-to-day business, for example in:

  • Research and development (particularly in clinical trials)
  • Patent enforcement
  • Regulatory authorisations
  • Advertising and distribution issues
  • Pricing strategies and reimbursements under social security law
  • Compliance
  • Data protection

We support our Healthcare clients in particular in the areas of:

  • Social security regulatory authorisations
  • Professional law
  • Data protection
  • Tariff negotiations and tariff settings
  • Planning (hospital planning, planning of highly-specialised medicine)
  • Liability issues and compliance

Whether you require professional support in the area of contracts, strategic agreements or in competition and antitrust law, or an expert opinion, are planning a corporate transaction or seek to engage in legal proceedings or are affected by legal, administrative or criminal proceedings, we would be delighted to assist you.

Industry knowledge

Many of our experts have worked in Life Sciences & Healthcare companies prior to joining CMS, gaining extensive knowledge in pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs, cosmetics and medical services. Through our active membership in the most important industry associations and our participation in the legislative process, we contribute to shaping the legal and regulatory framework for the Life Sciences & Healthcare sector.


Find out more in our Life Sciences & Healthcare brochure

Read more Read less

'Due to very good networking', CMS 'can provide know-how in a variety of matters', especially at a multi-jurisdictional level. Regulatory, compliance, financial benefits and pricing advice, as well as the negotiation of agreements and representation in court form the main areas of expertise.

The Legal 500, Healthcare and life sciences, Switzerland, 2019
17/04/2018
Life Sci­ences & Health­care Prac­tice Group Switzer­land

Feed

Show only
08 Jul 19
CMS ad­vises Bruker on the ac­quis­i­tion of PMOD Tech­no­lo­gies...
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
26/04/2019
CMS once again one of the lead­ing law firms in Switzer­land
BIL­ANZ Rank­ing 2019
17 Jan 20
New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
16 Apr 19
CMS Switzer­land fur­ther im­proves its rank­ing with The...
15 Jan 20
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
03 Apr 19
CMS ad­vises Op­tim­apharm Group on the ac­quis­i­tion of...
23 Dec 19
So­cial Me­dia and mHealth Data EMA / HMA Re­port
New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...
27 Feb 19
CMS ad­vised Syn­cona Ltd on in­vest­ment in Ana­ve­on AG
20 Dec 19
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
17 Dec 19
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....